Last reviewed · How we verify
Valbenazine Oral Capsule
Valbenazine Oral Capsule, marketed by Stephen Ruedrich, is a therapeutic option for patients with a specific neurological condition, though the exact indication is not specified. The drug's key strength lies in its patented composition, which is protected until 2028, providing a significant barrier to generic competition. However, the primary risk is the lack of detailed revenue data and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Valbenazine Oral Capsule |
|---|---|
| Also known as | Ingrezza |
| Sponsor | Stephen Ruedrich |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia (PHASE3)
- Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults (PHASE2)
- Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia (PHASE4)
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor (PHASE4)
- Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy (PHASE3)
- Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease (PHASE3)
- Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities (PHASE4)
- Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valbenazine Oral Capsule CI brief — competitive landscape report
- Valbenazine Oral Capsule updates RSS · CI watch RSS
- Stephen Ruedrich portfolio CI